Literature DB >> 27770170

Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies.

Joseph M Obeid1, Nolan A Wages2, Yinin Hu1, Donna H Deacon1, Craig L Slingluff3.   

Abstract

INTRODUCTION: Infiltration of non-small-cell lung cancer (NSCLC) by CD8+ T lymphocytes predicts improved patient survival; however, heterogeneity of intratumoral localization complicates this assessment. Strategies for tumor sampling may not accurately represent the whole tumor. We hypothesized that sampling strategies may alter the identification of tumors with high CD8 density and affect the prognostic significance. PATIENTS AND METHODS: Twenty-three primary NSCLC tumors were immunohistochemically stained for CD8 and were assessed using automated software with eight different sampling strategies or the whole tumor. Results of all sampling strategies were compared to the whole tumor counts (paired t tests, Pearson's r). Associations between CD8 densities and overall survival were assessed (log-rank test).
RESULTS: Counts from all eight sampling strategies significantly correlated with whole tumor counts (p ≤ 0.001). However, the magnitude of CD8+ cell counts and categorization into high vs low infiltrate groups were affected by the sampling strategy. The most concordant values were derived from random sampling of 20 % of the tumor, a simulated core biopsy, or from sampling the tumor center. TIL infiltration was associated with survival when sampling the center (p = 0.038), but not the invasive margin (p > 0.2) or other strategies.
CONCLUSION: Different tumor sampling strategies may yield discordant TIL density results and different stratification for risk assessment. Small biopsies may be particularly unrepresentative. Random sampling of larger tumor areas is recommended. Enumerating CD8+ T cells in the tumor center may have prognostic value.

Entities:  

Keywords:  CD8 T cells; Heterogeneity; NSCLC; Patient survival; Tumor sampling strategies; Tumor-infiltrating lymphocytes

Mesh:

Year:  2016        PMID: 27770170      PMCID: PMC5512540          DOI: 10.1007/s00262-016-1908-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  44 in total

1.  CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.

Authors:  Fayçal Djenidi; Julien Adam; Aïcha Goubar; Aurélie Durgeau; Guillaume Meurice; Vincent de Montpréville; Pierre Validire; Benjamin Besse; Fathia Mami-Chouaib
Journal:  J Immunol       Date:  2015-02-27       Impact factor: 5.422

2.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

3.  Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis.

Authors:  Yiting Geng; Yingjie Shao; Wenting He; Wenwei Hu; Yanjie Xu; Jun Chen; Changping Wu; Jingting Jiang
Journal:  Cell Physiol Biochem       Date:  2015-10-30

4.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

5.  Lung cancer histologic and immunohistochemical heterogeneity in the era of molecular therapies: analysis of 172 consecutive surgically resected, entirely sampled pulmonary carcinomas.

Authors:  Annamaria Cadioli; Giulio Rossi; Matteo Costantini; Alberto Cavazza; Mario Migaldi; Thomas V Colby
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

6.  The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer.

Authors:  Naoko Inoshima; Yoichi Nakanishi; Takahiro Minami; Miiru Izumi; Koichi Takayama; Ichiro Yoshino; Nobuyuki Hara
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

7.  Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer.

Authors:  Hui Liu; Tiantuo Zhang; Jin Ye; Hongtao Li; Jing Huang; Xiaodong Li; Benquan Wu; Xubing Huang; Jinghui Hou
Journal:  Cancer Immunol Immunother       Date:  2012-03-29       Impact factor: 6.968

Review 8.  Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.

Authors:  T Donnem; T K Kilvaer; S Andersen; E Richardsen; E E Paulsen; S M Hald; S Al-Saad; O T Brustugun; A Helland; M Lund-Iversen; S Solberg; B H Gronberg; S G F Wahl; L Helgeland; O Fløtten; M Pohl; K Al-Shibli; T M Sandanger; F Pezzella; L T Busund; R M Bremnes
Journal:  Ann Oncol       Date:  2015-11-16       Impact factor: 32.976

9.  Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Authors:  Kurt A Schalper; Jason Brown; Daniel Carvajal-Hausdorf; Joseph McLaughlin; Vamsidhar Velcheti; Konstantinos N Syrigos; Roy S Herbst; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2015-02-03       Impact factor: 11.816

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

View more
  13 in total

Review 1.  Integrative Pharmacology: Advancing Development of Effective Immunotherapies.

Authors:  Mohammad Tabrizi; Daping Zhang; Vaishnavi Ganti; Glareh Azadi
Journal:  AAPS J       Date:  2018-04-27       Impact factor: 4.009

2.  Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma.

Authors:  Sita S Withers; Daniel York; Jin W Choi; Kevin D Woolard; Renee Laufer-Amorim; Ellen E Sparger; Jenna H Burton; Stephen J McSorley; Arta M Monjazeb; William J Murphy; Robert J Canter; Robert B Rebhun
Journal:  Vet Comp Oncol       Date:  2019-04-08       Impact factor: 2.613

3.  Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).

Authors:  Young Kwang Chae; Sangmin Chang; Taeyeong Ko; Jonathan Anker; Sarita Agte; Wade Iams; Wooyoung M Choi; Kyoungmin Lee; Marcelo Cruz
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

4.  A four-factor immune risk score signature predicts the clinical outcome of patients with spinal chordoma.

Authors:  Ming-Xiang Zou; Yue Pan; Wei Huang; Tao-Lan Zhang; David Escobar; Xiao-Bin Wang; Yi Jiang; Xiao-Ling She; Guo-Hua Lv; Jing Li
Journal:  Clin Transl Med       Date:  2020-01

5.  Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.

Authors:  Sonja Althammer; Tze Heng Tan; Andreas Spitzmüller; Lorenz Rognoni; Tobias Wiestler; Thomas Herz; Moritz Widmaier; Marlon C Rebelatto; Helene Kaplon; Diane Damotte; Marco Alifano; Scott A Hammond; Marie-Caroline Dieu-Nosjean; Koustubh Ranade; Guenter Schmidt; Brandon W Higgs; Keith E Steele
Journal:  J Immunother Cancer       Date:  2019-05-06       Impact factor: 13.751

6.  Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.

Authors:  Yoshiya Matsumoto; Kenji Sawa; Mitsuru Fukui; Jun Oyanagi; Motohiro Izumi; Koichi Ogawa; Tomohiro Suzumura; Tetsuya Watanabe; Hiroyasu Kaneda; Shigeki Mitsuoka; Kazuhisa Asai; Tatsuo Kimura; Nobuyuki Yamamoto; Yasuhiro Koh; Tomoya Kawaguchi
Journal:  Cancer Sci       Date:  2019-08-30       Impact factor: 6.716

7.  Verification of the methodology for evaluating tumor-infiltrating lymphocytes in colorectal cancer.

Authors:  Shinji Matsutani; Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tatsunari Fukuoka; Yasuhito Iseki; Kosei Hirakawa; Masaichi Ohira
Journal:  Oncotarget       Date:  2018-03-08

Review 8.  Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers.

Authors:  Ivana Catacchio; Anna Scattone; Nicola Silvestris; Anita Mangia
Journal:  Transl Oncol       Date:  2018-05-03       Impact factor: 4.243

9.  Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients.

Authors:  Francesca Bianchi; Massimo Milione; Patrizia Casalini; Giovanni Centonze; Valentino M Le Noci; Chiara Storti; Spyridon Alexiadis; Mauro Truini; Gabriella Sozzi; Ugo Pastorino; Andrea Balsari; Elda Tagliabue; Lucia Sfondrini
Journal:  Sci Rep       Date:  2019-10-03       Impact factor: 4.379

10.  Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues.

Authors:  Minyoung Kwak; Gulsun Erdag; Craig L Slingluff
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.